X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (606) 606
life sciences & biomedicine (600) 600
humans (529) 529
cardiovascular system & cardiology (500) 500
cardiac & cardiovascular systems (485) 485
female (408) 408
male (400) 400
aged (366) 366
middle aged (332) 332
heart failure (303) 303
prognosis (206) 206
abridged index medicus (183) 183
mortality (176) 176
risk factors (172) 172
treatment outcome (140) 140
heart failure - drug therapy (134) 134
heart failure - mortality (128) 128
follow-up studies (121) 121
prospective studies (110) 110
cardiovascular (102) 102
cardiac patients (98) 98
double-blind method (93) 93
aged, 80 and over (90) 90
hospitalization (85) 85
registries (85) 85
atrial fibrillation (79) 79
heart attacks (79) 79
heart failure - physiopathology (78) 78
time factors (76) 76
clinical trials (75) 75
drug therapy (75) 75
myocardial infarction (73) 73
cardiology (71) 71
cardiology and cardiovascular medicine (68) 68
cardiovascular disease (66) 66
heart failure - epidemiology (66) 66
proportional hazards models (66) 66
care and treatment (65) 65
heart attack (65) 65
risk assessment (63) 63
angiotensin-converting enzyme inhibitors - therapeutic use (61) 61
diabetes (61) 61
adult (60) 60
general & internal medicine (60) 60
italy - epidemiology (60) 60
medicine, general & internal (59) 59
clinical medicine (58) 58
myocardial infarction - drug therapy (56) 56
patient outcomes (56) 56
analysis (53) 53
comorbidity (53) 53
kardiologi (53) 53
heart failure - diagnosis (52) 52
kaplan-meier estimate (50) 50
klinisk medicin (50) 50
multivariate analysis (50) 50
myocardial infarction - mortality (50) 50
peripheral vascular disease (50) 50
heart failure - blood (49) 49
cardiac and cardiovascular systems (47) 47
retrospective studies (47) 47
registry (46) 46
valsartan (46) 46
cardiovascular diseases (44) 44
randomized controlled trials as topic (44) 44
stroke (44) 44
acute disease (43) 43
incidence (43) 43
patients (43) 43
hospitalization - statistics & numerical data (42) 42
outcomes (42) 42
europe - epidemiology (41) 41
heart failure - complications (41) 41
hypertension (41) 41
prevalence (41) 41
chronic disease (40) 40
heart failure - therapy (39) 39
research (38) 38
tetrazoles - therapeutic use (38) 38
valine - analogs & derivatives (38) 38
electrocardiography (37) 37
myocardial infarction - complications (37) 37
stroke volume (37) 37
acute heart failure (36) 36
survival analysis (36) 36
italy (35) 35
medicin och hälsovetenskap (35) 35
heart diseases (34) 34
usage (34) 34
diabetes mellitus (33) 33
medical and health sciences (33) 33
survival rate (33) 33
cardiac arrhythmia (32) 32
cause of death (32) 32
drug therapy, combination (32) 32
epidemiology (32) 32
survival rate - trends (32) 32
confidence intervals (31) 31
recurrence (31) 31
valine - therapeutic use (31) 31
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (959) 959
Italian (31) 31
Spanish (7) 7
German (4) 4
Portuguese (3) 3
Japanese (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 10/2019, Volume 381, Issue 17, pp. 1609 - 1620
Patients with heart failure with preserved ejection fraction were assigned to receive sacubitril–valsartan or valsartan. At a median of 35 months, there was no... 
MIDDLE CHILD | MIDRANGE | IMPAIRED SYSTOLIC FUNCTION | SPIRONOLACTONE | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Valsartan - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Hospitalization - statistics & numerical data | Male | Tetrazoles - administration & dosage | Cardiovascular Diseases - mortality | Female | Aminobutyrates - administration & dosage | Double-Blind Method | Valsartan - adverse effects | Hypotension - chemically induced | Heart Failure - drug therapy | Stroke Volume | Neprilysin - antagonists & inhibitors | Sex Factors | Quality of Life | Angioedema - chemically induced | Aged | Tetrazoles - adverse effects | Angiotensin Receptor Antagonists - administration & dosage | Angiotensin Receptor Antagonists - adverse effects | Heart failure | Treatment outcome | Care and treatment | Usage | Safety and security measures | Hospitals | Patient outcomes | Analysis | Angiotensin | Causes of | Statistics | Admission and discharge | Renal function | Cardiomyopathy | Mortality | Angioedema | Clinical trials | Hospitalization | Coronary artery disease | Hypotension | Heart rate | Hyperkalemia | Patient safety | Death | Neprilysin | Heart diseases | Pharmaceuticals | Ejection fraction | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2017, Volume 377, Issue 13, pp. 1228 - 1239
This trial, which compared once-weekly exenatide plus usual care with usual care alone in patients with type 2 diabetes with or without previous cardiovascular... 
Medicine(all) | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Exenatide | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Venoms - administration & dosage | Female | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Drug Administration Schedule | Venoms - adverse effects | Kaplan-Meier Estimate | Diabetes Mellitus, Type 2 - blood | Least-Squares Analysis | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Usage | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Drug therapy | Observations | Myocardial infarction | Cerebral infarction | Diabetes mellitus | Pancreatitis | Amylin | Cardiovascular disease | Patients | Thyroid carcinoma | Studies | Side effects | Pancreatic carcinoma | Pancreatic cancer | Diabetes | Health risk assessment | Heart diseases | Endocrinology | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2019, Volume 381, Issue 26, pp. 2497 - 2505
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 375, Issue 9716, pp. 735 - 742
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2015, Volume 373, Issue 23, pp. 2247 - 2257
In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Acute Coronary Syndrome - drug therapy | Myocardial Infarction - complications | Acute Coronary Syndrome - complications | Angina, Unstable - complications | Diabetes Mellitus, Type 2 - mortality | Treatment Failure | Cardiovascular Diseases - epidemiology | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - adverse effects | Peptides - therapeutic use | Type 2 diabetes | Treatment outcome | Care and treatment | Analysis | Hypoglycemic agents | Dosage and administration | Acute coronary syndrome | Myocardial infarction | Cerebral infarction | Glucagon | Diabetes mellitus | Hypersensitivity | Pancreatitis | Angina | Glucose | Hypoglycemia | Morbidity | Studies | Heart rate | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Pancreas | Drug therapy | Diabetes mellitus (non-insulin dependent) | Heart diseases | Glucagon-like peptide 1 | Clinical trials | Regulatory approval | Hemoglobin | Drug dosages | Heart failure | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9689, pp. 525 - 533
Journal Article
The American heart journal, ISSN 0002-8703, 04/2016, Volume 174, pp. 103 - 110
Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide–1 receptor agonist, which can improve glycemic control, body... 
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Risk Assessment - methods | United States - epidemiology | Glucagon-Like Peptide 1 | Prognosis | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Peptides - administration & dosage | Incidence | Dose-Response Relationship, Drug | Microspheres | Hypoglycemic Agents - administration & dosage | Time Factors | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Venoms - administration & dosage | Adult | Female | Diabetes Mellitus, Type 2 - complications | Cardiovascular Diseases - etiology | Survival Rate - trends | Double-Blind Method | Drug Administration Schedule | Risk Factors | China - epidemiology | Diabetes Mellitus, Type 2 - blood | Ontario - epidemiology | Italy - epidemiology | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | United Kingdom - epidemiology | Type 2 diabetes | Hypoglycemic agents | Glucagon | Cardiac patients | Heart attack | Corporate sponsorship | Heart attacks | Research & development--R&D | Pragmatism | Cardiovascular disease | Diabetes | Pharmaceutical industry | Patients | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article